BioSpace News Archive

BioIVT, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland.

Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in the global HERTHENA-Lung02 phase 3 trial evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus platinum-based chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with disease progression following treatment with one or more EGFR tyrosine kinase inhibitors (TKIs) including a third-generation EGFR TKI.

Pear Therapeutics, Inc. and SelectHealth announced today that reSET-O®, the only FDA- authorized PDT to treat opioid use disorder (OUD), has been added as a covered benefit for SelectHealth’s members.

Sesen Bio (Nasdaq: SESN ) today reported operating results for the second quarter ended June 30, 2022.

Persephone Biosciences, Inc. today announced that it has enrolled the first subject in its My Baby Biome™ observational study to determine specific biomarkers that are associated with a healthy infant gut.

BIOQuébec’s Board of Directors is proud to announce the appointment of Emmanuelle Toussaint as Executive Director, effective immediately.

Cyclo Therapeutics, Inc. today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the 2022 China Nieman Pick Medical Exchange.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced that it has entered into a loan agreement with Avenue Venture Opportunities Fund, L.P. (“Avenue”) for up to $45 million of funding.

Inhibikase Therapeutics, Inc. today announced that it will report financial results for the second quarter ended June 30, 2022 on Friday, August 12, 2022, after the market closes.

Alercell ® announced today that it has started the distribution of AmoyDx ROS1 Gene Fusion Detection Kit. Part of the master distribution agreement with Amoy Diagnostics Co., Ltd (AmoyDx), signed last month.